Active	Status	Sponsor type	Region	Phase	Filter
3 Active 2 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Laurell, Anna
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma	Recruiting	3	870	Europe	R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)	Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum	Mantle Cell Lymphoma	05/21	05/26
Glimelius, Ingrid
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma	Recruiting	3	870	Europe	R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)	Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum	Mantle Cell Lymphoma	05/21	05/26
ALTAMIRA, NCT05214183: Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma	Active, not recruiting	2	81	Europe, RoW	Acalabrutinib-rituximab in patients with untreated mantle cell lymphoma	Nordic Lymphoma Group, AstraZeneca	MCL, Mantle Cell Lymphoma	01/27	01/27